AlzeCure Pharma AB is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe disorders that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallell drug candidates based on the three research platforms, NeuroRestore®, Alzstatin® and Painless.
NeuroRestore comprises three symptom-relieving drug candidates where the unique target mechanism opens up for multiple indications – Alzheimer’s disease, but also cognitive dysfunction in traumatic brain injury, sleep apnea and Parkinson’s disease. Alzstatin is comprised of two disease modifying and preventive drug candidates for treatment of early Alzheimer’s disease. Painless, which is the company’s research platform in the field of pain, contains two projects: VR1/ACD440 which is a clinical candidate for the treatment of neuropathic pain, and TrkA-NAM that is targeting pain disorders such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to an early clinical phase. FNCA Sweden AB, +46(0)8-528 00 399, email@example.com, is the company’s certified adviser.